| The Role of Bacterial Toxins in Human Skin Disease (NCT02910791) | National Jewish Health | 2019-02-20 |
| Ultrasound Enthesitis Response in Psoriatic Arthritis (NCT03955861) | Belfast Health and Social Care Trust | 2019-02-14 |
| An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis (NCT03777436) | Amgen | 2019-02-11 |
| FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis (NCT03820934) | University Hospitals Cleveland Medical Center | 2019-02-10 |
| A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis (NCT03818035) | Janssen-Cilag International NV | 2019-02-08 |
| Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males (NCT03873415) | Bristol-Myers Squibb | 2019-01-25 |
| Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions (NCT03629379) | Universitaire Ziekenhuizen KU Leuven | 2019-01-22 |
| Clinical, Psychological and Genetic Characteristics in Dermatological Patients (NCT03831646) | Astana Medical University | 2019-01-20 |
| Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (NCT03832738) | Akros Pharma Inc. | 2019-01-17 |
| Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis (NCT03827876) | Psoriasis Treatment Center of Central New Jersey | 2019-01-16 |
| Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin (NCT03423004) | Centre Hospitalier Régional d'Orléans | 2019-01-11 |
| Efficacy of Low Dose Naltrexone in Psoriasis (NCT04250792) | Jinnah Postgraduate Medical Centre | 2019-01-01 |
| A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC (NCT03661866) | Target PharmaSolutions, Inc. | 2018-12-21 |
| Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis (NCT03701763) | Amgen | 2018-12-19 |
| Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP) (NCT04515732) | Professor Mikkel Østergaard | 2018-12-14 |
| Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers. (NCT03798236) | Palobiofarma SL | 2018-12-10 |
| Psoriatic Arthritis and Psoriasis Treatment Decision Aid (NCT03737045) | University of Pennsylvania | 2018-12-01 |
| Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment (NCT03791216) | Northwestern University | 2018-12-01 |
| A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (NCT03733353) | Evelo Biosciences, Inc. | 2018-11-19 |
| Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis (NCT03597620) | University of Alabama at Birmingham | 2018-11-07 |
| Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis (NCT03431974) | Syntrix Biosystems, Inc. | 2018-11-01 |
| A Study of Mirikizumab in Participants With Plaque Psoriasis (NCT03718884) | Eli Lilly and Company | 2018-10-23 |
| The Effectiveness of a Mindful Parenting Intervention for Parents of Children With Psoriasis and Parents of Children With Eczema (NCT03873142) | University of Sheffield | 2018-10-19 |
| Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study (NCT03626714) | Auritec Pharmaceuticals | 2018-10-16 |
| A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers (NCT03577626) | Tianjin Hemay Bio-Tech Co., Ltd | 2018-10-10 |
| A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France (NCT03757013) | Amgen | 2018-09-25 |
| This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is (NCT03635099) | Boehringer Ingelheim | 2018-09-17 |
| Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis (NCT03478280) | Aarhus University Hospital | 2018-09-15 |
| A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) (NCT03556202) | Eli Lilly and Company | 2018-09-03 |
| Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin (NCT05203354) | Mahmoud Ahmed Ali Ahmed | 2018-09-01 |
| Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis (NCT04173039) | Association pour la Recherche Clinique et Immunologique | 2018-08-29 |
| A Study of AK111 in Healthy Subjects (NCT03622021) | Akesobio Australia Pty Ltd | 2018-08-14 |
| Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis (NCT03624127) | Bristol-Myers Squibb | 2018-08-07 |
| Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris (NCT03662685) | University of California, San Francisco | 2018-08-01 |
| A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis (NCT03384745) | Bond Avillion 2 Development LP | 2018-07-31 |
| A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis (NCT03219437) | AbbVie | 2018-07-30 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (NCT03611751) | Bristol-Myers Squibb | 2018-07-26 |
| A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis (NCT03971825) | Celgene | 2018-07-24 |
| Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis (NCT03587194) | Psoriasis Treatment Center of Central New Jersey | 2018-07-23 |
| Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (NCT03518047) | AbbVie | 2018-07-19 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (NCT03451851) | Janssen Research & Development, LLC | 2018-07-11 |
| Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects (NCT03570346) | Tianjin Hemay Bio-Tech Co., Ltd | 2018-07-10 |
| A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) (NCT03535194) | Eli Lilly and Company | 2018-06-26 |
| Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain (NCT03539419) | Amgen | 2018-06-12 |
| Aggressive Weight Loss Program in Chronic Plaque Psoriasis (NCT03531528) | San Giuseppe Moscati Hospital | 2018-05-21 |
| Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color (NCT03506477) | Icahn School of Medicine at Mount Sinai | 2018-05-21 |
| Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases (NCT03339089) | AbbVie | 2018-05-18 |
| A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis (NCT03465696) | Wake Forest University Health Sciences | 2018-05-14 |
| Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis (NCT03478787) | AbbVie | 2018-05-08 |
| Revitalization of Damaged Skin Due to Chronic Skin Diseases (NCT03485560) | Ace Cells Lab Limited | 2018-05-01 |
| Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis (NCT03469336) | Pfizer | 2018-04-24 |
| A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (NCT03482011) | Eli Lilly and Company | 2018-04-24 |
| A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis (NCT03493269) | Bayer | 2018-04-16 |
| Effect of Sublimated Mare Milk Supplement on Gut Microbiome in Psoriasis Patients (NCT03594877) | Nazarbayev University Medical Center | 2018-04-01 |
| Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) (NCT03540160) | Vyne Therapeutics Inc. | 2018-03-15 |
| 12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN (NCT03511755) | Thync Global, Inc. | 2018-03-12 |
| An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants (NCT03419910) | Bristol-Myers Squibb | 2018-03-05 |
| Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy (NCT03483311) | Cairo University | 2018-03-01 |
| Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome (NCT03440736) | Novartis Pharmaceuticals | 2018-02-28 |
| Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis (NCT03706209) | MetrioPharm AG | 2018-02-27 |
| Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis (NCT03453190) | Washington Dermatology Center | 2018-02-25 |
| The PsoTeenQOL - Preliminary Reliability and Validity (NCT03358914) | University of Aarhus | 2018-02-20 |
| A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis (NCT03418493) | Eli Lilly and Company | 2018-01-30 |
| A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) (NCT03421197) | Dr. Reddy's Laboratories Limited | 2018-01-25 |
| GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis (NCT03202004) | GlaxoSmithKline | 2018-01-22 |
| Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis (NCT02918123) | Kang Stem Biotech Co., Ltd. | 2018-01-17 |
| This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357 (NCT03279978) | Boehringer Ingelheim | 2018-01-09 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis (NCT03337022) | Celgene | 2018-01-04 |
| Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis (NCT03381625) | BioMimetix JV, LLC | 2018-01-02 |
| A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects (NCT03201978) | GlaxoSmithKline | 2017-12-14 |
| Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis (NCT03409211) | NYU Langone Health | 2017-12-12 |
| Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis (NCT03392168) | Arcutis Biotherapeutics, Inc. | 2017-12-11 |
| The Effect of Vitamin D Supplementation on Psoriasis Severity (NCT03334136) | University Hospital of North Norway | 2017-11-24 |
| Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service (NCT03223012) | AbbVie | 2017-11-15 |
| An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients (NCT03392337) | Psoriasis Treatment Center of Central New Jersey | 2017-11-07 |
| A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis (NCT03329885) | Bristol-Myers Squibb | 2017-11-02 |
| Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies (NCT03403036) | Icahn School of Medicine at Mount Sinai | 2017-10-31 |
| Ovarian Reserve in Patients With Psoriasis (NCT03492632) | Kanuni Sultan Suleyman Training and Research Hospital | 2017-10-25 |
| A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis (NCT03218488) | Janssen-Cilag International NV | 2017-10-25 |
| A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis (NCT03445013) | Novan, Inc. | 2017-10-13 |
| Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis (NCT03265613) | Guangdong Provincial Hospital of Traditional Chinese Medicine | 2017-09-24 |
| Chronic Inflammatory Disease, Lifestyle and Treatment Response (NCT03173144) | University of Southern Denmark | 2017-09-21 |
| A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation (NCT03254784) | Bristol-Myers Squibb | 2017-09-13 |
| A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China (NCT03236870) | AbbVie | 2017-09-08 |
| Post-Marketing Surveillance Study of OTEZLA (NCT03284879) | Amgen | 2017-09-05 |
| The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients (NCT03262727) | Bristol-Myers Squibb | 2017-09-01 |
| A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy (NCT03255382) | AbbVie | 2017-08-22 |
| Skin Tape Harvesting for Transcriptomics Analysis (NCT03048721) | University of Michigan | 2017-08-14 |
| Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions (NCT03198390) | University of Arizona | 2017-08-04 |
| LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis (NCT03254667) | Bausch Health Americas, Inc. | 2017-07-25 |
| The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis (NCT03210259) | Boehringer Ingelheim | 2017-07-10 |
| Immune Metabolic Associations in Psoriatic Arthritis (NCT03399708) | NHS Greater Glasgow and Clyde | 2017-06-12 |
| Assessing Patient Confidence in Biologic Medications (NCT03168347) | Wake Forest University Health Sciences | 2017-06-01 |
| Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients (NCT03135548) | Boehringer Ingelheim | 2017-05-30 |
| Safety and Efficacy of Secukinumab in Mild Psoriasis (NCT03131570) | James G. Krueger, MD, PhD | 2017-05-23 |
| A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp (NCT03123471) | Amgen | 2017-05-16 |
| Development of a Method to Measure mRNA Levels in Skin Samples (NCT04537468) | Innovaderm Research Inc. | 2017-05-11 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis (NCT03145948) | AbbVie | 2017-05-09 |
| Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 (NCT03179605) | Primus Pharmaceuticals | 2017-05-02 |
| Enstilar in Combination With Biologic Agents (NCT03080545) | Psoriasis Treatment Center of Central New Jersey | 2017-05-01 |